IL257940B - Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof - Google Patents

Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof

Info

Publication number
IL257940B
IL257940B IL257940A IL25794018A IL257940B IL 257940 B IL257940 B IL 257940B IL 257940 A IL257940 A IL 257940A IL 25794018 A IL25794018 A IL 25794018A IL 257940 B IL257940 B IL 257940B
Authority
IL
Israel
Prior art keywords
ccl22
seq
cells
peptide
sequence identity
Prior art date
Application number
IL257940A
Other languages
English (en)
Hebrew (he)
Other versions
IL257940A (en
Original Assignee
Herlev Hospital
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Herlev Hospital, Io Biotech Aps filed Critical Herlev Hospital
Publication of IL257940A publication Critical patent/IL257940A/en
Publication of IL257940B publication Critical patent/IL257940B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001142—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4236—Chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL257940A 2015-09-16 2016-09-16 Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof IL257940B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201570591 2015-09-16
PCT/DK2016/050301 WO2017045691A1 (en) 2015-09-16 2016-09-16 Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof

Publications (2)

Publication Number Publication Date
IL257940A IL257940A (en) 2018-05-31
IL257940B true IL257940B (en) 2022-08-01

Family

ID=57123753

Family Applications (1)

Application Number Title Priority Date Filing Date
IL257940A IL257940B (en) 2015-09-16 2016-09-16 Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof

Country Status (8)

Country Link
US (3) US11298413B2 (cg-RX-API-DMAC7.html)
EP (1) EP3349785A1 (cg-RX-API-DMAC7.html)
JP (1) JP6924747B2 (cg-RX-API-DMAC7.html)
CN (2) CN108472345B (cg-RX-API-DMAC7.html)
AU (1) AU2016322506B2 (cg-RX-API-DMAC7.html)
HK (1) HK1257448A1 (cg-RX-API-DMAC7.html)
IL (1) IL257940B (cg-RX-API-DMAC7.html)
WO (1) WO2017045691A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6924747B2 (ja) * 2015-09-16 2021-08-25 アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ Ｃ−ｃモチーフケモカイン２２（ｃｃｌ２２）またはこのフラグメントを含むワクチン組成物
US20210060052A1 (en) * 2018-03-15 2021-03-04 Atossa Therapeutics, Inc. In situ methods of inducing of immune response
FR3084463B1 (fr) * 2018-07-30 2023-04-21 Francais Du Sang Ets Procede d'analyse des plaquettes d'un echantillon sanguin
US20230256069A1 (en) * 2020-07-30 2023-08-17 Centro De Inmunología Molecular Use of epidermal growth factor depleting agents in the treatment of chronic obstructive pulmonary disease
WO2024168311A2 (en) * 2023-02-09 2024-08-15 The Brigham And Women’S Hospital, Inc. Autonomous gene circuits for therapy release

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
US7018627B1 (en) * 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
EP0778892A1 (en) 1995-06-07 1997-06-18 Icos Corporation Macrophage derived chemokine and chemokine analogs
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US8563476B2 (en) * 2002-11-15 2013-10-22 Morehouse School Of Medicine Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3 and anti-CXCR5 agents for inflammatory disorders
WO2004093871A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel methods for the treatment of cancer
EP2628749A3 (en) * 2006-06-20 2013-12-04 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Antimicrobial kinocidin compostions and methods of use
PL3320912T3 (pl) 2008-04-17 2021-10-25 Io Biotech Aps Immunoterapia na bazie 2,3-dioksygenazy indoloaminy
US8846098B2 (en) * 2009-07-10 2014-09-30 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Artificial cell constructs for cellular manipulation
WO2011139738A2 (en) 2010-04-28 2011-11-10 Tenx Biopharma, Inc. Therapies using zanolimumab to enhance the immune response
SI2768524T1 (sl) 2011-10-17 2022-09-30 Io Biotech Aps Imunoterapija na osnovi PD-L1
AU2013206896B2 (en) * 2012-01-03 2017-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Native and agonist CTL epitopes of the MUC1 tumor antigen
US20150359869A1 (en) 2012-08-15 2015-12-17 Cyvax, Inc. Methods and compositions for preventing a condition
CA2883711A1 (en) * 2012-09-07 2014-03-13 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
FI3461491T3 (fi) 2013-04-18 2025-02-20 Tilt Biotherapeutics Oy Tehostettu adoptiivinen soluterapia
US10130454B2 (en) 2014-08-01 2018-11-20 Iowa State University Research Foundation, Inc. Vaccine delivery devices
JP6924747B2 (ja) * 2015-09-16 2021-08-25 アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ Ｃ−ｃモチーフケモカイン２２（ｃｃｌ２２）またはこのフラグメントを含むワクチン組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018627B1 (en) * 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor

Also Published As

Publication number Publication date
CA2998789A1 (en) 2017-03-23
US20230241191A9 (en) 2023-08-03
AU2016322506A1 (en) 2018-04-12
EP3349785A1 (en) 2018-07-25
WO2017045691A9 (en) 2018-06-28
US20190008939A1 (en) 2019-01-10
US12496333B2 (en) 2025-12-16
US20220280624A1 (en) 2022-09-08
AU2016322506A9 (en) 2018-12-06
CN108472345A (zh) 2018-08-31
JP2018528960A (ja) 2018-10-04
AU2016322506B2 (en) 2023-02-09
JP6924747B2 (ja) 2021-08-25
IL257940A (en) 2018-05-31
CN108472345B (zh) 2023-05-23
US11298413B2 (en) 2022-04-12
US20220339273A1 (en) 2022-10-27
NZ740930A (en) 2024-09-27
CN116333088A (zh) 2023-06-27
HK1257448A1 (zh) 2019-10-18
WO2017045691A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
US12233103B2 (en) Indoleamine 2,3-dioxygenase based immunotherapy
CA2850245C (en) Pd-l1 based immunotherapy
US12496333B2 (en) Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof
US11878053B2 (en) Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
CA2998789C (en) Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof
HK1247114A1 (en) Indoleamine 2, 3-dioxygenase based immunotherapy